Drug Trial Radar · NCT06248619
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
89
Actual
Start
Jul 5, 2024
Primary completion
Dec 23, 2025
Study completion Nov 13, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Feb 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
Conditions
- Thyroid Eye Disease
Interventions
TeprotumumabBiological
SC injection
PlaceboOther
SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proptosis responder rate (percentage of participants with a ≥ 2-mm reduction from baseline in proptosis in the study eye without deterioration [≥ 2-mm increase] of proptosis in the fellow eye).Time frame: Week 24
Locations
38 sites in 11 countries. Site status is shown where the registry gives one.
Catalina Eye Care - NVISION - PPDS
Tucson, Arizona
Advanced Quality Medical Research
Orland Park, Illinois
W Kellogg Eye Center
Ann Arbor, Michigan
Las Vegas Endocrinology
Henderson, Nevada
The Center for Eye and Facial Plastic Surgery
Somerset, New Jersey
Casey Eye Institute -515 SW Campus Dr
Portland, Oregon
Scheie Eye Institute
Philadelphia, Pennsylvania
University of Tennessee Health Science Center - 848 Adams Ave
Memphis, Tennessee
Baylor College of Medicine-1977 Butler Blvd
Houston, Texas
University of Washington Eye Institute
Seattle, Washington
West Virginia University Eye Institute
Morgantown, West Virginia
Hospital Universitario Austral
Pilar, Buenos Aires, Argentina
Organización Médica de Investigación
Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina
Centro Medico Grupo Laser Vision
Rosario, Santa Fe Province, Argentina
Sydney Eye Hospital
Sydney, New South Wales, Australia
Queensland Eye Institute
Wooloongabba, Queensland, Australia
Royal Adelaide Hospital
Adelaie, South Australia, Australia
Centre For Eye Research Australia Ltd
East Melbourne, Victoria, Australia
CHU de Quebec-Universite Laval CUO Recherche Clinique Hopital du St-Sacrement
Québec, Canada
Vancouver Coastal Health Research Institute (VCHRI) - 2550 Willow St
Vancouver, British Columbia, Canada
McGill University Health Centre Research Institute
Montreal, Quebec, Canada
AP-HM-Hôpital de La Conception
Marseille, Bouches-du-Rhône, France
Universitätsklinikum Essen
Essen, North Rhine-Westphalia, Germany
Azienda Ospedaliero Universitaria Pisana - Stabilimento di Cisanello
Pisa, Italy
Azienda Ospedaliero Universitaria Pisana - Stabilimento Santa Chiara
Pisa, Italy
Azienda Ospedaliera Universitaria Federico II
Naples, Campania, Italy
Hayashi Eye Hospital
Fukuoka, Hukuoka, Japan
Kozawa Eye hospital and Diabetes Center
Mito, Ibaraki, Japan
Ishikawa Prefectural Central Hospital
Kanazawa, Ishikawa-ken, Japan
University of Miyazaki Hospital
Miyazaki, Miyazaki, Japan
Gokeikai Osaka Kaisei Hospital
Osaka-Shi Yodogawa-Ku, Ôsaka, Japan
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Hospital Universitari i Politecnic La Fe de Valencia-Avda de Fernando Abril Martorell 106
Valencia, Spain
Changhua Christian Hospital
Changhua County, Taiwan
Chung Shan Medical University Hospital
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Moorfields Eye Hospital - PPDS
London, Middlesex, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.